Cefepime/Zidebactam
- Generic Name
- Cefepime/Zidebactam
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Phase 1
Recruiting
- Conditions
- PHA1A
- Interventions
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 30
- Registration Number
- NCT06806995
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
Plasma and Intrapulmonary Concentrations Study of WCK 5222
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 36
- Registration Number
- NCT03630094
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers
Phase 1
Completed
- Conditions
- QT/QTc Interval in Healthy Volunteers
- Interventions
- Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 60
- Registration Number
- NCT03554304
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 48
- Registration Number
- NCT02942810
- Locations
- 🇺🇸
University of Miami,Division of Clinical Pharmacology, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath